Research Article

Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer

Figure 4

Galunisertib reversed TGF-β1-dependent downregulation of NKp30, NKp46, NKG2D, and DNAM-1 expression on NK cells. Purified NK cells from healthy donors were treated with 5 μM TGF-β receptor I inhibitor galunisertib (G) for 1 hour followed by 10 ng/ml rhTGF-β1 stimulation. After 48 hours, the expression of NKp30, NKp46, NKG2D, and DNAM-1 on NK cells were detected by flow cytometry (). ; .